Inhaled study drug for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational drug given through an inhaler for people with advanced non-small cell lung cancer that has not spread beyond the chest. It aims to see if the treatment is safe, tolerable, and effective at shrinking tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have non-small cell lung cancer that is stage I–III but has come back or persists in the chest despite prior treatment.
- You must be able to perform breathing tests and use an inhaler.
- You must not have cancer that has spread to other organs (like the brain, bones, or liver).
- You must have quit smoking for at least 6 months and agree to not smoke or inhale substances during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests a new study drug (HS-10504) given along with other treatments for advanced non-small cell lung cancer that has not responded to earlier therapy. The goal is to see if adding this drug can help control the cancer and shrink tumors.
This trial tests a new drug (HS-10504) to see how it affects another medicine called midazolam (used for sedation). The goal is to understand how HS-10504 is processed in the body, which may help in future dosing. Participation may provide access to a new treatment option.
This study tests an inhaled study drug before lung cancer surgery to see if it helps. You may join if you have a new diagnosis of a common type of lung cancer and are scheduled for surgery or radiation.
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.